

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

### **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rules 17.06A, 17.06B and 17.06C of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that on April 8, 2024, the Company has resolved to grant share options (the “**Options**”) to eligible participants (the “**Grantees**”), who are employees of the Group, to subscribe for up to 14,323,805 ordinary shares of the Company of US\$0.000005 each (the “**Shares**”) in the capital of the Company pursuant to the share scheme adopted by the Company on June 27, 2023 (the “**Share Scheme**”), subject to the acceptance of the Grantees.

Details of the Options are as follows:

Date of Grant: April 8, 2024 (the “**Date of Grant**”).

Number of the Grantees: 36 Grantees (including two Directors and 34 employees).

Exercise price of the Options granted: HK\$1.002 per Share, representing the highest of (i) the closing price of HK\$0.900 per Share as stated in the daily quotations sheet issued by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on the Date of Grant; (ii) the average closing price of HK\$1.002 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share of US\$0.000005.

- Number of Options granted: 14,323,805 Options (each Option shall entitle the holder of the Option to subscribe for one Share).
- Validity period of the Options: Ten (10) years from the Date of Grant.
- Vesting period of the Options: Among the total Options:
- (i) 6,808,580 Options shall be vested on April 8, 2029;
  - (ii) 2,565,225 Options shall be vested in the following manners: half of the Options shall be vested on April 8, 2026, and the rest shall be vested in tranches on the last trading day of each month during the period from May 2026 to April 2028 (inclusive); and
  - (iii) 4,950,000 Options shall be vested in five (5) years, 1/5 of which shall be vested on each anniversary of the Date of Grant.
- Performance targets: The vesting of the Options is not subject to any performance targets.
- The purpose of the Share Scheme is to provide incentive to eligible participants in order to promote the development and success of the business of the Group. The Options to be granted will give the Grantees an opportunity to have a personal stake in the Company and will help motivate the Grantees in optimizing their performance and efficiency. The number of Options to be granted are based on the work performance and potential of the Grantees and no additional performance target is imposed before the Options are vested to the Grantees. In view of the above, the remuneration committee of the Company considered the grant of Options aligned with the purpose of the Share Scheme.
- Clawback mechanism: The Options granted will be subject to the clawback mechanism as set out in the Share Scheme and the offer letter of the grant of Options as determined by the Board, in particular, the lapse of Options upon cessation of employment of the Grantees and the cancellation of Options at the discretion of the Board.
- Financial assistance: There is no arrangement for the Group to provide any financial assistance to the Grantees to facilitate the purchase of the Shares under the Share Scheme.

Among the Grantees, 2,748,444 Options were granted to the Directors, with details as follows:

<b>Name</b>	<b>Position</b>	<b>Number of Options</b>
Zhao Liang	Executive Director	1,876,016
Yan Luying	Executive Director	872,428

In accordance with the Rule 17.04(1) of the Listing Rules, the independent non-executive Directors have approved the grant of the above Options to the Directors.

The remaining 11,575,361 Options were granted to 34 employees of the Group.

None of the Options will be subject to approval by the independent shareholders of the Company (being the shareholders of the Company other than the relevant Grantee(s), their associates (as defined under the Listing Rules)), and save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiry, none of the Grantees is a participant with options and awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D of the Listing Rules; or a related entity participant or service provider (as defined in Listing Rules) with options and awards granted and to be granted in any 12-month period exceeding 0.1% of the total issued Shares.

After the grant of the Options, the number of Shares available for future grant under the mandate of the Share Scheme is 213,898,549.

By order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Chen Guoming**  
*Chairman*

Shanghai, PRC, April 8, 2024

*As of the date of this announcement, the executive Directors of the Company are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors of the Company are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.*